ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 201 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 1.47 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,715,610 | -14.7% | 105,576 | -3.0% | 0.00% | 0.0% |
Q1 2024 | $2,012,119 | -44.0% | 108,822 | -5.2% | 0.00% | -40.0% |
Q4 2023 | $3,592,478 | +43.4% | 114,739 | -4.6% | 0.01% | +25.0% |
Q3 2023 | $2,505,322 | -25.4% | 120,217 | -14.3% | 0.00% | -20.0% |
Q2 2023 | $3,358,676 | +17.9% | 140,237 | -7.4% | 0.01% | +25.0% |
Q1 2023 | $2,849,781 | +16.5% | 151,423 | -1.4% | 0.00% | 0.0% |
Q4 2022 | $2,445,646 | -1.4% | 153,621 | +1.3% | 0.00% | 0.0% |
Q3 2022 | $2,481,000 | +14.1% | 151,653 | -1.7% | 0.00% | +33.3% |
Q2 2022 | $2,174,000 | -41.6% | 154,302 | +0.3% | 0.00% | -40.0% |
Q1 2022 | $3,725,000 | -4.3% | 153,782 | -7.8% | 0.01% | 0.0% |
Q4 2021 | $3,894,000 | +43.6% | 166,818 | +2.2% | 0.01% | +66.7% |
Q3 2021 | $2,712,000 | -38.2% | 163,279 | -9.3% | 0.00% | -50.0% |
Q2 2021 | $4,389,000 | -20.2% | 179,968 | -15.6% | 0.01% | -14.3% |
Q1 2021 | $5,500,000 | -52.0% | 213,169 | -0.5% | 0.01% | -56.2% |
Q4 2020 | $11,457,000 | +32.3% | 214,318 | +2.1% | 0.02% | +14.3% |
Q3 2020 | $8,659,000 | -5.1% | 209,916 | +11.5% | 0.01% | -12.5% |
Q2 2020 | $9,126,000 | +26.3% | 188,285 | +10.1% | 0.02% | 0.0% |
Q1 2020 | $7,228,000 | -1.7% | 171,084 | -0.5% | 0.02% | +23.1% |
Q4 2019 | $7,355,000 | +24.5% | 171,931 | +4.7% | 0.01% | +8.3% |
Q3 2019 | $5,909,000 | +36.3% | 164,176 | +1.2% | 0.01% | +33.3% |
Q2 2019 | $4,336,000 | -6.9% | 162,215 | -6.4% | 0.01% | -10.0% |
Q1 2019 | $4,656,000 | +86.9% | 173,394 | +12.6% | 0.01% | +66.7% |
Q4 2018 | $2,491,000 | -20.3% | 154,048 | +2.3% | 0.01% | 0.0% |
Q3 2018 | $3,126,000 | +35.9% | 150,574 | -0.0% | 0.01% | +20.0% |
Q2 2018 | $2,300,000 | -32.0% | 150,628 | +0.0% | 0.01% | -28.6% |
Q1 2018 | $3,384,000 | -27.9% | 150,582 | -3.4% | 0.01% | -30.0% |
Q4 2017 | $4,693,000 | -19.9% | 155,861 | +0.2% | 0.01% | -23.1% |
Q3 2017 | $5,858,000 | +22.0% | 155,504 | -9.7% | 0.01% | +30.0% |
Q2 2017 | $4,801,000 | -26.5% | 172,137 | -9.4% | 0.01% | -23.1% |
Q1 2017 | $6,534,000 | +14.1% | 190,060 | -4.3% | 0.01% | +8.3% |
Q4 2016 | $5,729,000 | -11.7% | 198,660 | -2.6% | 0.01% | -7.7% |
Q3 2016 | $6,491,000 | +4.6% | 204,060 | +6.7% | 0.01% | 0.0% |
Q2 2016 | $6,208,000 | +24.0% | 191,260 | +6.8% | 0.01% | +18.2% |
Q1 2016 | $5,005,000 | -4.9% | 179,004 | +21.2% | 0.01% | -15.4% |
Q4 2015 | $5,265,000 | +9.5% | 147,687 | +1.6% | 0.01% | 0.0% |
Q3 2015 | $4,807,000 | -21.1% | 145,364 | -0.1% | 0.01% | -13.3% |
Q2 2015 | $6,096,000 | +29.5% | 145,564 | +0.8% | 0.02% | +36.4% |
Q1 2015 | $4,707,000 | +1.2% | 144,426 | -1.4% | 0.01% | 0.0% |
Q4 2014 | $4,652,000 | +29.1% | 146,526 | +0.7% | 0.01% | +22.2% |
Q3 2014 | $3,603,000 | +10.9% | 145,504 | +1.1% | 0.01% | +12.5% |
Q2 2014 | $3,250,000 | -4.9% | 143,878 | +2.4% | 0.01% | -11.1% |
Q1 2014 | $3,418,000 | +7.8% | 140,478 | +10.7% | 0.01% | 0.0% |
Q4 2013 | $3,171,000 | -8.4% | 126,878 | +0.7% | 0.01% | -10.0% |
Q3 2013 | $3,461,000 | +56.2% | 125,978 | +3.2% | 0.01% | +42.9% |
Q2 2013 | $2,216,000 | – | 122,113 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Fairmount Funds Management LLC | 647,833 | $26,723,000 | 11.32% |
GREAT POINT PARTNERS LLC | 1,921,563 | $79,264,000 | 7.13% |
Baker Brothers Advisors | 41,904,586 | $1,728,564,000 | 6.91% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 486,000 | $20,048,000 | 6.47% |
Palo Alto Investors LP | 1,832,300 | $75,582,000 | 4.15% |
Birchview Capital, LP | 204,000 | $8,416,000 | 2.81% |
SECTORAL ASSET MANAGEMENT INC | 556,514 | $22,956,000 | 1.97% |
Rock Springs Capital Management LP | 1,573,200 | $64,895,000 | 1.65% |
Riggs Asset Managment Co. Inc. | 17,470 | $2,025,000 | 0.85% |
PFM Health Sciences, LP | 421,087 | $17,370,000 | 0.80% |